References
- Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898–909.
- Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141–157.
- Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047–2060.
- Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, Syed IS, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007;116:2420–2426.
- Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 1983;52:137–146.
- Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS. Bleeding manifestations in 100 patients with amyloidosis. JAMA 1983;249:1322–1324.
- Hoshino Y, Hatake K, Muroi K, Tsunoda S, Suzuki T, Miwa A, Sakamoto S, Miura Y. Bleeding tendency caused by the deposit of amyloid substance in the perivascular region. Intern Med 1993;32:879–881.
- Furie B, Voo L, McAdam KP, Furie BC. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 1981;304:827–830.
- Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O’Hara C, Connors L, et al. Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol 2007;82:363–367.
- Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia. Med Lab Sci 1983;40:165–175.
- Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002;87:1076–1077.
- Marmont AM, Merlini G. Monoclonal autoimmunity in hematology. Haematologica 1991;76:449–459.
- Vaziri ND, Paule P, Toohey J, Hung E, Alikhani S, Darwish R, Pahl MV. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 1984;144:1802–1803.
- Gamba G, Montani N, Anesi E, Palladini G, Lorenzutti F, Perfetti V, Merlini G. Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. Amyloid 1999;6:273–277.
- Browne RS, Schneiderman H, Kayani N, Radford MJ, Hager WD. Amyloid heart disease manifested by systemic arterial thromboemboli. Chest 1992;102:304–307.
- Hausfater P, Costedoat-Chalumeau N, Amoura Z, Cacoub P, Papo T, Grateau G, Leblond V, et al. AL cardiac amyloidosis and arterial thromboembolic events. Scand J Rheumatol 2005;34:315–319.
- Halligan CS, Lacy MQ, Vincent Rajkumar S, Dispenzieri A, Witzig TE, Lust JA, Fonseca R, et al. Natural history of thromboembolism in AL amyloidosis. Amyloid 2006;13:31–36.
- Feng D, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, Edwards WD, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119:2490–2497.
- Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492–496.
- Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465–470.